Tumor Inhibition by Enzalutamide in a Xenograft Model of Ovarian Cancer. (25th November 2016)

• Record Type: Journal Article
• Authors: Park, Brian Y.; Grisham, Rachel N.; den Hollander, Bjørnar; Thapi, Dharmarao; Berman, Tara; de Stanchina, Elisa; Zhou, Qin; Iyer, Gopa; Aghajanian, Carol; Spriggs, David R.
• Is Part Of: Cancer investigation. Volume 34:Number 10(2016)
• Page Start: 517
• Page End: 520
• Publication Date: 2016-11-25
• Subjects: Enzalutamide -- androgen receptor -- epithelial ovarian cancer -- OVCAR-3 -- xenograft; Cancer -- Periodicals; Oncology -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- Periodicals; 616.994
• DOI: 10.1080/07357907.2016.1242598
• Languages: English
• ISSNs: 0735-7907

Abstract

ABSTRACT: Objectives : To investigate the tumor-suppressive properties of enzalutamide in androgen-driven ovarian cancer. Methods : Mice were implanted subcutaneously with OVCAR-3 cells and treated with dihydrotestosterone in combination with enzalutamide or vehicle control. Tumor volumes were measured twice weekly until day 56. Results : Dihydrotestosterone exposure led to a significant increase in tumor growth, while concomitant treatment with enzalutamide led to significant reductions in tumor volume compared to the androgen-exposed groups. Conclusions : We present the first evidence that the second-generation anti-androgen enzalutamide may possess efficacy in the treatment of ovarian cancer, paving the way for the future clinical trials.